Performance of Anti–Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established Disease
- 26 August 2013
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (9), 2243-2252
- https://doi.org/10.1002/art.38017
Abstract
Objective To compare the diagnostic accuracy and agreement of commonly available assays for anti–citrullinated protein antibodies in patients with established rheumatoid arthritis (RA) and subjects at increased risk of RA. Methods Tests for anti–cyclic citrullinated peptide (anti‐CCP) antibodies were performed using CCP2 IgG and CCP3.1 IgA/IgG enzyme‐linked immunosorbent assays in the following groups: probands with established RA (n = 340) from the Studies of the Etiology of Rheumatoid Arthritis (SERA) cohort and their first‐degree relatives (FDRs) without inflammatory arthritis (n = 681), Department of Defense Serum Repository (DoDSR) RA cases with pre–RA diagnosis samples (n = 83; 47 cases also had post–RA diagnosis samples), and blood donor and DoDSR control subjects (n = 283). Results In patients with established RA, the CCP2 assay was more specific (99.2% versus 93.1%; P < 0.01) but less sensitive (58.7% versus 67.4%; P = 0.01) than the CCP3.1 assay; the specificity of the CCP3.1 assay increased to 97.2% when cutoff levels ≥3‐fold the standard level were considered. In all subjects, CCP3.1 assay positivity (using standard cutoff levels) was more prevalent. Among DoDSR cases, the CCP2 assay was more specific than the CCP3.1 for predicting a future diagnosis of RA, and higher CCP levels trended toward increasing specificity for the development of RA within 2 years. At standard cutoff levels, assay agreement was good in patients with established RA (κ = 0.76) but poor in FDRs without inflammatory arthritis (κ = 0.25). Conclusion Anti‐CCP assays differ to an extent that may be meaningful for diagnosing RA in patients with inflammatory arthritis and evaluating the natural history of RA development in subjects at risk of RA. The mechanisms underlying these differences in test performance need further investigation.Keywords
Funding Information
- NIH (AI-050864, AR-051394, AI-61479, AR-07534, AR-051461)
- Arthritis Foundation
- Walter S. and Lucienne Driskill Foundation
This publication has 28 references indexed in Scilit:
- Anti–Citrullinated Protein Antibodies in Unaffected First‐Degree Relatives of Rheumatoid Arthritis PatientsArthritis & Rheumatism, 2013
- Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid ArthritisPLOS ONE, 2012
- Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptidesArthritis Research & Therapy, 2012
- Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritisArthritis Research & Therapy, 2011
- The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age‐dependent mannerArthritis & Rheumatism, 2010
- Preclinical Rheumatoid Arthritis: Identification, Evaluation, and Future Directions for InvestigationRheumatic Disease Clinics of North America, 2010
- A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first‐degree relatives of probands with RAArthritis Care & Research, 2009
- Comparison of Threshold Cutpoints and Continuous Measures of Anti-Cyclic Citrullinated Peptide Antibodies in Predicting Future Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritisClinical Rheumatology, 2008
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988